FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Occuments Cited by Applicant						Application No.:	10/559,311	
						Filing Date:	April 28, 2006	
						First Named Inventor:	Koh-Ichi Sakata	
						Group:	1643	
						Examiner:	Gussow, Anne	
						Attorney Docket No.:	1603/2	
- Contract of the Contract of	TATRAP	MAR	-	U.S. PATE	ENT DO	CUMENTS		
Examiner Initial	Cite No.	Document Number F		lication Date	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, where relevant passages o relevant figures appear	
,								
		-	F(OREIGN PA	ATENT	DOCUMENTS		•
Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known)		Publication Date		Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	Т
			2					
	•			OTHER	R DOC	JMENTS		
Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.						
/AMG/	1.	Supplemental European Search Report for PCT/JP03/07079 dated November 3, 2006						
/AMG/	2.	Auckley, Dennis H. et al., "Reduced DNA-dependent protein kinase activity is associated with lung cancer", Carcinogenesis, vol. 22, no.5, pp.723-727.						
/AMG/	3.	Jhappan, C., et al., "DNA-PKcs: a T-cell tumour suppressor encoded at the Mouse scid locus", Nature Genetics, vol 17, no.4, December 1997, pp. 483-486.						
/AMG/	4.	Yu, Yongjia, et al., "Elevated Breast Cancer Risk in Irradiated BALB/c Mice Associates with Unique Functional Polymorphism of the <i>Prkdc</i> (DNA-dependent Protein Kinase Catalytic Subunit) Gene", Cancer Research, vol. 61, no. 5, 1 March 2001, pp. 1820-1824.						
/AMG/	5. Someya, Masanori, et al., "The association of DNA-dependent protein kinase activity with chromosomal instability and risk of cancer", Carcinogenesis, vol. 27, no.1, January 2006, pp. 117-122.							
FXAMINE	11	Anne Gussow/		D/	TE CC	NSIDERED 04/04/200	7	

DATE CONSIDERED _

EXAMINER _

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through *Examiner citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORMETO-1449 U.S. Department of Commerce 10/559,311 Application No.: Patent and Trademark Office December 1, 2005 Filing Date: First Named Inventor: Koh-Ichi Sakata List of Documents Cited by Applicant To Be Assigned Group: To Be Assigned Examiner: 1603/2 Attorney Docket No.: -U.S. PATENT DOCUMENTS Name of Patentee or Applicant of Cited Pages, Columns, Lines, **Publication Date Document Number** Examiner Cite Document where relevant passages or Initial No. relevant figures appear FOREIGN PATENT DOCUMENTS **Publication Date** Name of Patentee or Applicant Pages, columns, lines Examiner Cite **Document Number** where relevant Initials No. (country code, no., kind passages appear code (if known) Sumitomo Chem Co Ltd. 08/15/1989 JP 01-202298 A /AMG/ 1. 03/06/2002 Medical & Biological 2. EP 1184665 A1 /AMG/ Laboratories Co., Ltd. OTHER DOCUMENTS Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc. Cite Examiner Initials No. International Search Report for PCT/JP03/07079 dated July 15, 2003 /AMG/ 1. 04/04/2007 /Anne Gussow/ DATE CONSIDERED _____ EXAMINER

JAN 17 2006

^{*}Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.